10x Genomics (TXG) 10-Q 5 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Oct. 31, 2021
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-39035
Entity Registrant Name	10x Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-5614458
Entity Address, Address Line One	6230 Stoneridge Mall Road
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	401-7300
Title of 12(b) Security	Class A common stock, par value $0.00001 per share
Trading Symbol	TXG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001770787
Common Class A
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		91,585,992
Common Class B
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		20,121,465

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 600,440	$ 663,603
Restricted cash	28	16,567
Accounts receivable, net	78,430	51,208
Inventory	51,141	29,959
Prepaid expenses and other current assets	14,065	13,029
Total current assets	744,104	774,366
Property and equipment, net	142,589	72,840
Restricted cash	8,597	8,474
Operating lease right-of-use assets	60,715	46,983
Goodwill	4,511	0
Other non-current assets	30,056	26,678
Total assets	990,572	929,341
Current liabilities:
Accounts payable	17,037	4,709
Accrued compensation and related benefits	27,182	15,383
Accrued expenses and other current liabilities	46,187	43,453
Deferred revenue	5,505	4,472
Operating lease liabilities	4,464	5,936
Accrued contingent liabilities	0	44,173
Total current liabilities	100,375	118,126
Accrued license fee, noncurrent	5,814	11,171
Operating lease liabilities, noncurrent	75,735	57,042
Other noncurrent liabilities	8,427	3,930
Total liabilities	190,351	190,269
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock	0	0
Common stock	2	2
Additional paid-in capital	1,644,897	1,544,218
Accumulated deficit	(844,872)	(805,098)
Accumulated other comprehensive gain (loss)	194	(50)
Total stockholders’ equity	800,221	739,072
Total liabilities and stockholders’ equity	$ 990,572	$ 929,341

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue	$ 125,297	$ 71,817	$ 346,960	$ 186,627
Cost of revenue	24,518	14,411	46,493	39,571
Gross profit	100,779	57,406	300,467	147,056
Operating expenses:
Research and development	54,582	30,143	149,867	83,670
In-process research and development	0	40,637	0	40,637
Selling, general and administrative	62,076	51,549	187,683	146,352
Accrued contingent liabilities	0	332	(660)	956
Total operating expenses	116,658	122,661	336,890	271,615
Loss from operations	(15,879)	(65,255)	(36,423)	(124,559)
Other income (expense):
Interest income	49	28	157	1,471
Interest expense	(219)	(397)	(649)	(1,365)
Other (expense) income, net	(599)	361	(807)	121
Loss on extinguishment of debt	0	0	0	(1,521)
Total other expense	(769)	(8)	(1,299)	(1,294)
Loss before provision for income taxes	(16,648)	(65,263)	(37,722)	(125,853)
Provision for income taxes	523	585	2,052	1,305
Net loss	(17,171)	(65,848)	(39,774)	(127,158)
Other comprehensive income:
Foreign currency translation adjustment	136	(366)	244	(6)
Comprehensive loss	$ (17,035)	$ (66,214)	$ (39,530)	$ (127,164)
Net loss per share, basic (in dollars per share)	$ (0.15)	$ (0.65)	$ (0.36)	$ (1.28)
Net loss per share, diluted (in dollars per share)	$ (0.15)	$ (0.65)	$ (0.36)	$ (1.28)
Weighted-average shares of common stock used in computing net loss per share, basic (in shares)	110,874,249	101,341,945	109,826,104	99,058,139
Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)	110,874,249	101,341,945	109,826,104	99,058,139

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Common Class A	Common Class ACommon Stock	Common Class AAdditional Paid-in Capital
Beginning balance (in shares) at Dec. 31, 2019		96,241,596
Beginning balance at Dec. 31, 2019	$ 420,083	$ 2	$ 682,494	$ (262,367)	$ (46)
Issuance of Class A common stock related to equity awards (in shares)							1,903,612
Issuance of Class A common stock related to equity awards						$ 3,283		$ 3,283
Vesting of shares subject to repurchase, including early exercised options	122		122
Stock-based compensation	6,718		6,718
Net loss	(21,143)			(21,143)
Other comprehensive income	5				5
Ending balance (in shares) at Mar. 31, 2020		98,145,208
Ending balance at Mar. 31, 2020	409,068	$ 2	692,617	(283,510)	(41)
Beginning balance (in shares) at Dec. 31, 2019		96,241,596
Beginning balance at Dec. 31, 2019	420,083	$ 2	682,494	(262,367)	(46)
Net loss	(127,158)
Ending balance (in shares) at Sep. 30, 2020		105,599,976
Ending balance at Sep. 30, 2020	825,080	$ 2	1,214,655	(389,525)	(52)
Beginning balance (in shares) at Mar. 31, 2020		98,145,208
Beginning balance at Mar. 31, 2020	409,068	$ 2	692,617	(283,510)	(41)
Issuance of Class A common stock related to equity awards (in shares)							2,113,974
Issuance of Class A common stock related to equity awards						8,051		8,051
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	13,920		13,920
Net loss	(40,167)			(40,167)
Other comprehensive income	355				355
Ending balance (in shares) at Jun. 30, 2020		100,259,182
Ending balance at Jun. 30, 2020	391,269	$ 2	714,630	(323,677)	314
Sale of Class A common stock (in shares)							4,600,000
Sale of Class A common stock						482,279		482,279
Issuance of Class A common stock related to equity awards (in shares)							740,794
Issuance of Class A common stock related to equity awards						3,920		3,920
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	13,784		13,784
Net loss	(65,848)			(65,848)
Other comprehensive income	(366)				(366)
Ending balance (in shares) at Sep. 30, 2020		105,599,976
Ending balance at Sep. 30, 2020	825,080	$ 2	1,214,655	(389,525)	(52)
Beginning balance (in shares) at Dec. 31, 2020		108,485,909
Beginning balance at Dec. 31, 2020	739,072	$ 2	1,544,218	(805,098)	(50)
Issuance of Class A common stock related to equity awards (in shares)							1,102,618
Issuance of Class A common stock related to equity awards						8,546		8,546
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	16,253		16,253
Net loss	(11,551)			(11,551)
Other comprehensive income	98				98
Ending balance (in shares) at Mar. 31, 2021		109,588,527
Ending balance at Mar. 31, 2021	752,460	$ 2	1,569,059	(816,649)	48
Beginning balance (in shares) at Dec. 31, 2020		108,485,909
Beginning balance at Dec. 31, 2020	739,072	$ 2	1,544,218	(805,098)	(50)
Net loss	(39,774)
Ending balance (in shares) at Sep. 30, 2021		111,537,448
Ending balance at Sep. 30, 2021	800,221	$ 2	1,644,897	(844,872)	194
Beginning balance (in shares) at Mar. 31, 2021		109,588,527
Beginning balance at Mar. 31, 2021	752,460	$ 2	1,569,059	(816,649)	48
Issuance of Class A common stock related to equity awards (in shares)							1,151,392
Issuance of Class A common stock related to equity awards						16,194		16,194
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	26,932		26,932
Net loss	(11,052)			(11,052)
Other comprehensive income	10				10
Ending balance (in shares) at Jun. 30, 2021		110,739,919
Ending balance at Jun. 30, 2021	784,586	$ 2	1,612,227	(827,701)	58
Issuance of Class A common stock related to equity awards (in shares)							797,529
Issuance of Class A common stock related to equity awards						$ 6,682		$ 6,682
Vesting of shares subject to repurchase, including early exercised options	38		38
Stock-based compensation	25,950		25,950
Net loss	(17,171)			(17,171)
Other comprehensive income	136				136
Ending balance (in shares) at Sep. 30, 2021		111,537,448
Ending balance at Sep. 30, 2021	$ 800,221	$ 2	$ 1,644,897	$ (844,872)	$ 194

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities:
Net loss	$ (39,774)	$ (127,158)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	15,337	10,094
Stock-based compensation expense	69,058	34,357
Loss on disposal of property and equipment	66	0
Loss on extinguishment of debt	0	1,521
Accretion of discount on term loan	0	17
Amortization of right-of-use assets	5,593	3,511
Changes in operating assets and liabilities:
Accounts receivable	(27,216)	(2,654)
Inventory	(21,349)	(9,848)
Prepaid expenses and other current assets	(1,220)	(3,363)
Other assets	348	(2,574)
Accounts payable	12,191	(3,307)
Accrued compensation and other related benefits	11,868	(1,286)
Deferred revenue	1,221	898
Accrued contingent liabilities	(44,173)	8,900
Accrued expenses and other current liabilities	(2,545)	9,464
Operating lease liability	(2,498)	(3,093)
Other noncurrent liabilities	(4,085)	(3,202)
Net cash used in operating activities	(27,178)	(87,723)
Investing activities:
Acquisition of intangible assets	0	(801)
Acquisition of business, net of cash acquired	(5,451)	0
Purchases of property and equipment	(73,660)	(15,327)
Net cash used in investing activities	(79,111)	(16,128)
Financing activities:
Payments on financing arrangement	(5,028)	(5,846)
Payments on term loans	0	(31,256)
Proceeds from issuance of common stock from follow-on public offering, net of issuance costs	0	483,047
Issuance of common stock from exercise of stock options and employee stock purchase plan purchases	31,422	15,255
Net cash provided by financing activities	26,394	461,200
Effect of exchange rates on changes in cash, cash equivalents, and restricted cash	316	(144)
Net (decrease) increase in cash, cash equivalents, and restricted cash	(79,579)	357,205
Cash, cash equivalents, and restricted cash at beginning of period	688,644	476,493
Cash, cash equivalents, and restricted cash at end of period	609,065	833,698
Supplemental disclosures of cash flow information:
Cash paid for interest	1,222	1,670
Cash paid for taxes	8,318	224
Noncash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	12,710	14,183
Right-of-use assets obtained in exchange for new operating lease liabilities	19,566	10,883
Contingent consideration payable from business acquisition	1,536	0
Deferred offering costs in accounts payable and accrued expenses and other current liabilities	$ 0	$ 768

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Organization and Description of Business 10x Genomics, Inc. (the “Company”) was incorporated in the state of Delaware on July 2, 2012 and is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company’s integrated solutions include the Company’s Chromium Controller, Chromium Connect and Chromium X Series instruments, which the Company refers to as “instruments,” and the Company’s proprietary microfluidic chips, slides, reagents and other consumables for both the Company’s Visium and Chromium solutions, which the Company refers to as “consumables.” The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Canada, China, Denmark, Germany, Netherlands, Singapore, Sweden, the United States and the United Kingdom. Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2020 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates. The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the SEC on February 26, 2021 (our "Annual Report").

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Fair Value of Financial Instruments Cash and cash equivalents are comprised of money market funds and cash which are classified as Level 1 in the fair value hierarchy. As of September 30, 2021 and December 31, 2020, the Company held $548.0 million and $600.9 million in money market funds, respectively, with no unrealized gains or losses. Revenue Recognition The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component. The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities including awards under the Company’s equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.

Acquisition

Acquisition	9 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Acquisition	Acquisition On January 8, 2021 (the "acquisition date"), the Company purchased 100% of the outstanding shares of Tetramer Shop ApS (“Tetramer Shop”), a privately held company based in Copenhagen, Denmark, for a total cash consideration of $8.5 million, net of cash acquired of $0.2 million and including $1.5 million of estimated fair value of contingent consideration. The contingent consideration is recorded as a liability and is payable upon the successful transfer of Tetramer Shop's technology to the Company within two years of the acquisition date. Tetramer Shop is a life sciences technology company which develops and provides reagents for precise monitoring of antigen-specific T-cells in research and development. The Company acquired Tetramer Shop for its expertise in building empty, loadable major histocompatibility complex (MHC) molecules. The acquisition was accounted for using the acquisition method of accounting, with Tetramer Shop treated as the acquiree. The acquired assets, including identified intangible assets, and liabilities were recorded at their respective fair values with an amount recorded to goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets. The fair values assigned to the assets acquired and liabilities assumed were based on management’s assumptions as of the reporting date. Our condensed consolidated statements of income include the financial results of Tetramer Shop subsequent to the acquisition date. Revenue related to Tetramer Shop since the acquisition date was included in our condensed consolidated statements of income and was not material. The estimated fair value of assets acquired, including goodwill and intangibles, and liabilities assumed as of the acquisition date were as follows (in thousands): Amount Cash and cash equivalents $ 224 Other current assets 45 Property and equipment, net 38 Tangible assets acquired 307 Accrued expenses (555) Other current liabilities (97) Deferred tax liability - non-current (1,131) Total net tangible assets acquired and liabilities assumed (1,476) Intangible assets 5,640 Goodwill 4,511 Net assets acquired $ 8,675 The intangible assets as of the acquisition date included (in thousands): Amount Weighted Average Useful Life (in years) Developed technology $ 5,500 10 Customer relationships 140 3 $ 5,640 The fair value of the intangible assets acquired in connection with the acquisition was determined using either the income or replacement cost methodologies. The developed technology and customer relationships will be amortized over ten years and three years, respectively. Identifiable Intangible Assets Valuation of intangible assets involves multiple assumptions. The key assumptions are described below. Developed technology acquired primarily consists of existing technology related to developing reagents for precise monitoring of antigen-specific T cells in research and development, enabling the Company to strengthen its efforts in immunology. The Company valued the developed technology using the multi-period excess earnings method under the income approach. Using this approach, the estimated fair values were calculated using expected future cash flows discounted to their net present values at an appropriate risk-adjusted rate of return. Goodwill

Other Financial Statement Infor

Other Financial Statement Information	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Statement Information	Other Financial Statement Information Inventory Inventory was comprised of the following (in thousands): September 30, December 31, Purchased materials $ 25,995 $ 9,930 Work in progress 12,742 9,312 Finished goods 12,404 10,717 Inventory $ 51,141 $ 29,959 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): September 30, December 31, Land $ 35,692 $ — Laboratory equipment and machinery 42,017 30,010 Computer equipment and software 11,844 5,783 Furniture and fixtures 5,647 5,887 Leasehold improvements 52,941 42,068 Construction in progress 38,842 19,594 Total property and equipment 186,983 103,342 Less: accumulated depreciation and amortization (44,394) (30,502) Property and equipment, net $ 142,589 $ 72,840 Intangible Assets, Net Intangible assets, net, which are recorded within other assets in the condensed consolidated balance sheets, consisted of the following (dollars in thousands): September 30, 2021 December 31, 2020 Remaining Useful Life in Years Gross Accumulated Intangibles, Remaining Useful Life in Years Gross Accumulated Intangibles, Technology licenses 13.0 $ 22,504 $ (3,123) $ 19,381 13.7 $ 22,504 $ (1,973) $ 20,531 Developed technology 9.3 5,500 (413) 5,087 — — — — Customer relationships 3.0 945 (280) 665 3.9 805 (111) 694 Trademarks 0.1 204 (193) 11 0.9 204 (142) 62 Assembled workforce 4.0 1,128 (231) 897 4.8 1,128 (61) 1,067 Total intangible assets, net $ 30,281 $ (4,240) $ 26,041 $ 24,641 $ (2,287) $ 22,354 The estimated annual amortization of intangible assets for the next five years is shown below (in thousands): Estimated 2021 (excluding the nine months ended September 30, 2021) $ 645 2022 2,535 2023 2,506 2024 2,378 2025 2,214 Thereafter 15,763 Total $ 26,041 Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures and asset impairments, among other factors. Accrued Compensation and Related Benefits Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued payroll and related costs $ 3,470 $ 2,506 Employee stock purchase program liability 3,567 1,258 Accrued bonus 12,200 5,058 Accrued commissions 3,001 3,038 Accrued acquisition-related compensation 2,968 2,213 Accrued vacation 1,287 1,035 Other 689 275 Accrued compensation and related benefits $ 27,182 $ 15,383 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued legal and related costs $ 3,327 $ 5,704 Accrued license fee 5,999 6,198 Accrued purchase consideration 5,015 4,146 Accrued royalties for licensed technologies 4,143 3,160 Accrued property and equipment 12,515 2,983 Accrued professional services 5,400 3,137 Product warranties 824 399 Customer deposits 962 1,727 Taxes payable 3,300 8,649 Accrued lab supplies 1,875 1,506 Other 2,827 5,844 Accrued expenses and other current liabilities $ 46,187 $ 43,453 Product Warranties Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): Nine Months Ended September 30, 2021 Year Ended December 31, 2020 Beginning of period $ 399 $ 467 Amounts charged to cost of revenue 2,113 796 Repairs and replacements (1,688) (864) End of period $ 824 $ 399 Revenue and Deferred Revenue As of September 30, 2021, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of Chromium instruments, was $7.3 million, of which approximately $5.4 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $7.3 million and $6.2 million as of September 30, 2021 and December 31, 2020, respectively, consisted of deferred revenue related to extended warranty service agreements. Revenue recorded during the three and nine months ended September 30, 2021 included $0.9 million and $3.4 million, respectively, of previously deferred revenue that was included in contract liabilities as of December 31, 2020. Revenue recorded during the three and nine months ended September 30, 2020 included $0.7 million and $2.8 million, respectively, of previously deferred revenue that was included in contract liabilities as of December 31, 2019. The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Instruments $ 17,121 $ 9,676 $ 45,123 $ 26,108 Consumables 106,117 60,557 296,342 156,149 Services 2,059 1,584 5,495 4,370 Total revenue $ 125,297 $ 71,817 $ 346,960 $ 186,627 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 North America $ 70,228 $ 42,363 $ 187,800 $ 102,356 Europe, Middle East and Africa 25,819 15,497 73,761 40,370 China 19,063 8,689 55,577 27,314 Asia-Pacific (excluding China) 10,187 5,268 29,822 16,587 Total revenue $ 125,297 $ 71,817 $ 346,960 $ 186,627 Revenue for the United States, which is included in North America in the table above, was 55% and 57% of consolidated revenue for the three months ended September 30, 2021 and 2020, respectively, and 53% and 53% of consolidated revenue for the nine months ended September 30, 2021 and 2020, respectively.

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt	Debt In September 2016, the Company entered into a Second Amended and Restated Loan and Security Agreement with Silicon Valley Bank (as amended and restated in February 2018 and as further amended, restated or supplemented from time to time, the “Loan and Security Agreement”), which included a term loan and revolving line of credit. On February 20, 2020, the Company prepaid the remaining balance of the term loan and all associated costs. The final payment of $30.5 million included $28.3 million for the outstanding principal balance of the term loan, $1.8 million for an end of term payment, $0.3 million for early termination fees and $0.1 million for interest. The prepayment resulted in a loss on extinguishment of debt of $1.5 million. The non-accreted portion of the end of term payment, unamortized discounts and early termination fees were included in the calculation of the loss on extinguishment of debt. The revolving line of credit and the Loan and Security Agreement was terminated at the election of the Company on June 18, 2020. Upon termination, the Company incurred termination fees of $0.3 million. As of June 18, 2020, there were no balances outstanding under the revolving line of credit.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease Agreements The Company leases office, laboratory, manufacturing, distribution and server space with lease terms up to 12 years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. For the three and nine months ended September 30, 2021, the Company incurred $2.6 million and $7.9 million, respectively, of operating lease costs and $0.1 million and $0.5 million, respectively, of variable lease costs. For the three and nine months ended September 30, 2020, the Company incurred $2.1 million and $6.1 million, respectively, of operating lease costs and $19 thousand and $0.2 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. Cash paid for amounts included in the measurement of operating lease liabilities for the nine months ended September 30, 2021 and 2020 was $4.6 million and $5.1 million and were included in net cash used in operating activities in the Company’s condensed consolidated statements of cash flows. Future net lease payments related to the Company’s operating lease liabilities as of September 30, 2021 is as follows (in thousands): Operating Leases 2021 (excluding the nine months ended September 30, 2021) $ 464 2022 9,969 2023 11,637 2024 10,942 2025 11,152 Thereafter 59,746 Total lease payments $ 103,910 Less: imputed interest (23,711) Present value of operating lease liabilities $ 80,199 Operating lease liabilities, current $ 4,464 Operating lease liabilities, noncurrent $ 75,735 The following table summarizes additional information related to operating leases as of September 30, 2021: September 30, 2021 December 31, 2020 Weighted-average remaining lease term 7.6 years 8.4 years Weighted-average discount rate 5.4 % 4.5 % On November 6, 2020, the Company entered into a Master Lease Agreement ("MLA") to lease additional office building space near the Company's Pleasanton, California headquarters. The Company intends to utilize the leased space of approximately 145,000 square feet to accommodate its future growth requirements. The MLA consists of various lease components expected to commence on various dates between 2021 and 2023 and is expected to terminate on June 30, 2033 with total lease payments over the lease term expected to amount to approximately $60.8 million, net of a tenant improvement allowance of approximately $10.0 million to be received in 2021 and 2022. Approximately, $2.6 million of this allowance has been received as of September 30, 2021. Certain lease components of the MLA commenced on January 1, 2021 and July 1, 2021. Total undiscounted payments for leases commencing in fiscal years 2022 and 2023 will be $21.0 million and $14.0 million, respectively, with weighted-average expected lease terms of 12 years for 2022 and 11 years for 2023. On April 30, 2021, the Company entered into a lease agreement to lease office building space of approximately 22,000 square feet in Stockholm, Sweden to accommodate its future growth requirements. The Company expects the lease term to commence in January 2022 for a five-year term and expects total lease payments over the lease term to amount to approximately $5.7 million. The tables above do not include payments, lease term, or discount rates relating to any leases or lease components that have not yet commenced as of September 30, 2021. The Company will determine the classification for each lease component at the individual component's commencement date. All leases and lease components that have not yet commenced are expected to be classified as operating leases. Lease payments for leases not yet commenced as of September 30, 2021 is as follows (in thousands): Lease payments for leases not yet Commenced 2021 (excluding the nine months ended September 30, 2021) $ — 2022 1,054 2023 2,855 2024 4,342 2025 4,179 Thereafter 28,270 Total undiscounted lease payments $ 40,700 Litigation The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. The 2021 Bio-Rad Settlement And Patent Cross License Agreement Bio-Rad Laboratories, Inc. (“Bio-Rad”) and the Company were previously engaged in litigation and other proceedings relating to substantially all of the Company’s Chromium products, including the Company’s legacy GEM products and Next GEM products and multiple Bio-Rad products, around the world. On July 26, 2021, the Company entered into a Settlement and Patent Cross License Agreement (the “Bio-Rad Agreement”) with Bio-Rad resolving all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world and dismissing all infringement claims with prejudice. Pursuant to the terms of the Bio-Rad Agreement, Bio-Rad and the Company granted each other a non-exclusive, worldwide, royalty-bearing license to develop products and services related to single cell analysis. The cross license excludes spatial and In Situ products. It also excludes digital PCR products in the case of 10x. The term of the Bio-Rad Agreement is for the life of the licensed patents. The Company and Bio-Rad have agreed not to sue each other on licensed products and licensed services on other patents owned or exclusively licensed by each company. The companies have agreed that each company’s patents are owned by each respective company. Each company shall pay to the other royalties from licensed products and licensed services through 2030. Each company shall pay to the other royalties from licensed products and licensed services through 2030. The Company previously accrued $44.8 million in royalties and interest between November 14, 2018 and March 31, 2021 related to sales of the Company’s GEM products as a result of the litigation with Bio-Rad. Pursuant to the Agreement, the Company paid Bio-Rad $29.4 million in royalties and interest related to the sales of such GEM products between November 14, 2018 and March 31, 2021. As a result, in connection with the Agreement the Company reversed $15.4 million in accrued royalties and interest as a reduction in cost of goods sold and operating expenses in the second quarter of 2021. The Nanostring Action On May 6, 2021, the Company filed suit against Nanostring Technologies, Inc. ("Nanostring") in the U.S. District Court for the District of Delaware alleging that Nanostring's GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113, and 10,996,219. On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On July 1, 2021, Nanostring filed a motion to dismiss. Briefing is complete and a hearing has been scheduled for November 17, 2021. Discovery has just commenced; no case schedule has been set. For further discussion of the risks relating to intellectual property and our pending litigation, see the section titled “Risk Factors—Risks related to litigation and our intellectual property” under Item 1A below.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Capital Stock	Capital StockAs of September 30, 2021, the number of shares of Class A common stock and Class B common stock issued and outstanding was 91,255,983 and 20,281,465, respectively. During the three months ended September 30, 2020 and during the nine months ended September 30, 2021 and 2020, 2,153,783, 2,400,000 and 47,558,717 shares of Class B common stock, respectively, were converted to shares of Class A common stock upon the election of the holders of such shares. No conversions of Class B common stock to Class A common stock occurred during the three months ended September 30, 2021.

Equity Incentive Plans

Equity Incentive Plans	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Equity Incentive Plans	Equity Incentive Plans 2019 Employee Stock Purchase Plan A total of 3,084,859 shares of Class A common stock was reserved for issuance under the 2019 Employee Stock Purchase Plan ("ESPP"). The price at which Class A common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. Shares purchased under the ESPP are subject to a one-year holding period following the purchase date. During the nine months ended September 30, 2021 and 2020, 30,980 and 118,218 shares of Class A common stock, respectively, were issued under the ESPP. No shares of Class A common stock were issued under the ESPP during the three months ended September 30, 2021 or 2020. As of September 30, 2021, there were 2,888,340 shares available for issuance in connection under the ESPP. Stock-based Compensation The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cost of revenue $ 878 $ 398 $ 2,183 $ 1,108 Research and development 11,226 5,467 30,162 14,398 Selling, general and administrative 13,846 7,919 36,713 18,851 Total stock-based compensation expense $ 25,950 $ 13,784 $ 69,058 $ 34,357 Restricted Stock Units Restricted stock unit activity for the nine months ended September 30, 2021 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2020 823,947 $ 80.97 Granted 828,463 184.38 Vested (266,602) 106.14 Cancelled (71,651) 118.67 Outstanding as of September 30, 2021 1,314,157 $ 139.00 Stock Options Stock option activity for the nine months ended September 30, 2021 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2020 11,860,844 $ 18.86 Granted 363,874 178.40 Exercised (2,753,957) 10.11 Cancelled (263,911) 25.00 Outstanding as of September 30, 2021 9,206,850 $ 27.61

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Stock-options to purchase common stock 9,206,850 12,817,142 9,206,850 12,817,142 Shares subject to repurchase 25,000 84,375 25,000 84,375 Contingent restricted shares 236,484 — 236,484 — Restricted stock units 1,314,157 779,296 1,314,157 779,296 Shares committed under ESPP 29,178 39,449 29,178 39,449 Total 10,811,669 13,720,262 10,811,669 13,720,262

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2020 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates.
Fair Value of Financial Instruments	Fair Value of Financial InstrumentsCash and cash equivalents are comprised of money market funds and cash which are classified as Level 1 in the fair value hierarchy.
Revenue Recognition	Revenue Recognition The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component.
Net Loss Per Share	Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities including awards under the Company’s equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.

Acquisition (Tables)

Acquisition (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The estimated fair value of assets acquired, including goodwill and intangibles, and liabilities assumed as of the acquisition date were as follows (in thousands): Amount Cash and cash equivalents $ 224 Other current assets 45 Property and equipment, net 38 Tangible assets acquired 307 Accrued expenses (555) Other current liabilities (97) Deferred tax liability - non-current (1,131) Total net tangible assets acquired and liabilities assumed (1,476) Intangible assets 5,640 Goodwill 4,511 Net assets acquired $ 8,675
Schedule of Intangible Assets Acquired	The intangible assets as of the acquisition date included (in thousands): Amount Weighted Average Useful Life (in years) Developed technology $ 5,500 10 Customer relationships 140 3 $ 5,640

Other Financial Statement Inf_2

Other Financial Statement Information (Tables)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	Inventory was comprised of the following (in thousands): September 30, December 31, Purchased materials $ 25,995 $ 9,930 Work in progress 12,742 9,312 Finished goods 12,404 10,717 Inventory $ 51,141 $ 29,959
Schedule of Property, Plant and Equipment	Property and equipment, net consisted of the following (in thousands): September 30, December 31, Land $ 35,692 $ — Laboratory equipment and machinery 42,017 30,010 Computer equipment and software 11,844 5,783 Furniture and fixtures 5,647 5,887 Leasehold improvements 52,941 42,068 Construction in progress 38,842 19,594 Total property and equipment 186,983 103,342 Less: accumulated depreciation and amortization (44,394) (30,502) Property and equipment, net $ 142,589 $ 72,840
Schedule of Intangible Assets, Net	Intangible assets, net, which are recorded within other assets in the condensed consolidated balance sheets, consisted of the following (dollars in thousands): September 30, 2021 December 31, 2020 Remaining Useful Life in Years Gross Accumulated Intangibles, Remaining Useful Life in Years Gross Accumulated Intangibles, Technology licenses 13.0 $ 22,504 $ (3,123) $ 19,381 13.7 $ 22,504 $ (1,973) $ 20,531 Developed technology 9.3 5,500 (413) 5,087 — — — — Customer relationships 3.0 945 (280) 665 3.9 805 (111) 694 Trademarks 0.1 204 (193) 11 0.9 204 (142) 62 Assembled workforce 4.0 1,128 (231) 897 4.8 1,128 (61) 1,067 Total intangible assets, net $ 30,281 $ (4,240) $ 26,041 $ 24,641 $ (2,287) $ 22,354
Schedule of Annual Amortization of Intangible Assets	The estimated annual amortization of intangible assets for the next five years is shown below (in thousands): Estimated 2021 (excluding the nine months ended September 30, 2021) $ 645 2022 2,535 2023 2,506 2024 2,378 2025 2,214 Thereafter 15,763 Total $ 26,041
Schedule of Accrued Compensation and Related Benefits	Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued payroll and related costs $ 3,470 $ 2,506 Employee stock purchase program liability 3,567 1,258 Accrued bonus 12,200 5,058 Accrued commissions 3,001 3,038 Accrued acquisition-related compensation 2,968 2,213 Accrued vacation 1,287 1,035 Other 689 275 Accrued compensation and related benefits $ 27,182 $ 15,383
Schedule of Accrued Expense and Other Current Liabilities	Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued legal and related costs $ 3,327 $ 5,704 Accrued license fee 5,999 6,198 Accrued purchase consideration 5,015 4,146 Accrued royalties for licensed technologies 4,143 3,160 Accrued property and equipment 12,515 2,983 Accrued professional services 5,400 3,137 Product warranties 824 399 Customer deposits 962 1,727 Taxes payable 3,300 8,649 Accrued lab supplies 1,875 1,506 Other 2,827 5,844 Accrued expenses and other current liabilities $ 46,187 $ 43,453
Schedule of Changes in the Reserve for Product Warranties	Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): Nine Months Ended September 30, 2021 Year Ended December 31, 2020 Beginning of period $ 399 $ 467 Amounts charged to cost of revenue 2,113 796 Repairs and replacements (1,688) (864) End of period $ 824 $ 399
Schedule of Revenue by Source	The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Instruments $ 17,121 $ 9,676 $ 45,123 $ 26,108 Consumables 106,117 60,557 296,342 156,149 Services 2,059 1,584 5,495 4,370 Total revenue $ 125,297 $ 71,817 $ 346,960 $ 186,627
Schedule of Revenue by Geographic Location	The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 North America $ 70,228 $ 42,363 $ 187,800 $ 102,356 Europe, Middle East and Africa 25,819 15,497 73,761 40,370 China 19,063 8,689 55,577 27,314 Asia-Pacific (excluding China) 10,187 5,268 29,822 16,587 Total revenue $ 125,297 $ 71,817 $ 346,960 $ 186,627

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Summary of Company's Operating Lease Liabilities	Future net lease payments related to the Company’s operating lease liabilities as of September 30, 2021 is as follows (in thousands): Operating Leases 2021 (excluding the nine months ended September 30, 2021) $ 464 2022 9,969 2023 11,637 2024 10,942 2025 11,152 Thereafter 59,746 Total lease payments $ 103,910 Less: imputed interest (23,711) Present value of operating lease liabilities $ 80,199 Operating lease liabilities, current $ 4,464 Operating lease liabilities, noncurrent $ 75,735
Summary of Additional Information Related to Operating Leases	The following table summarizes additional information related to operating leases as of September 30, 2021: September 30, 2021 December 31, 2020 Weighted-average remaining lease term 7.6 years 8.4 years Weighted-average discount rate 5.4 % 4.5 %
Schedule of Estimated Undiscounted Lease Payments for Operating Lease, Lease Not Yet Commenced	Lease payments for leases not yet commenced as of September 30, 2021 is as follows (in thousands): Lease payments for leases not yet Commenced 2021 (excluding the nine months ended September 30, 2021) $ — 2022 1,054 2023 2,855 2024 4,342 2025 4,179 Thereafter 28,270 Total undiscounted lease payments $ 40,700

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations	The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cost of revenue $ 878 $ 398 $ 2,183 $ 1,108 Research and development 11,226 5,467 30,162 14,398 Selling, general and administrative 13,846 7,919 36,713 18,851 Total stock-based compensation expense $ 25,950 $ 13,784 $ 69,058 $ 34,357
Summary of RSU activity	Restricted stock unit activity for the nine months ended September 30, 2021 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2020 823,947 $ 80.97 Granted 828,463 184.38 Vested (266,602) 106.14 Cancelled (71,651) 118.67 Outstanding as of September 30, 2021 1,314,157 $ 139.00
Summary of the Company's Stock Option Activity	Stock option activity for the nine months ended September 30, 2021 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2020 11,860,844 $ 18.86 Granted 363,874 178.40 Exercised (2,753,957) 10.11 Cancelled (263,911) 25.00 Outstanding as of September 30, 2021 9,206,850 $ 27.61

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Stock-options to purchase common stock 9,206,850 12,817,142 9,206,850 12,817,142 Shares subject to repurchase 25,000 84,375 25,000 84,375 Contingent restricted shares 236,484 — 236,484 — Restricted stock units 1,314,157 779,296 1,314,157 779,296 Shares committed under ESPP 29,178 39,449 29,178 39,449 Total 10,811,669 13,720,262 10,811,669 13,720,262

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue recognition, payment due period	45 days
Fair Value, Inputs, Level 1 | Money Market Funds
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Fair value of money market instruments	$ 548	$ 600.9
Unrealized gains (losses) on money market instruments	$ 0	$ 0

Acquisition - Additional Inform

Acquisition - Additional Information (Details) - Tetramer Shop $ in Millions	Jan. 08, 2021USD ($)
Business Acquisition [Line Items]
Percentage of outstanding shares acquired	100.00%
Consideration transferred	$ 8.5
Cash acquired	0.2
Estimated fair value of contingent consideration	$ 1.5
Payment term	2 years
Developed technology
Business Acquisition [Line Items]
Weighted average useful life	10 years
Customer relationships
Business Acquisition [Line Items]
Weighted average useful life	3 years

Acquisition - Schedule of Asset

Acquisition - Schedule of Assets Acquired and Liabilities Assumed, Including Goodwill and Intangibles (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jan. 08, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 4,511		$ 0
Tetramer Shop
Business Acquisition [Line Items]
Cash and cash equivalents		$ 224
Other current assets		45
Property and equipment, net		38
Tangible assets acquired		307
Accrued expenses		(555)
Other current liabilities		(97)
Deferred tax liability - non-current		(1,131)
Total net tangible assets acquired and liabilities assumed		(1,476)
Intangible assets		5,640
Goodwill		4,511
Net assets acquired		$ 8,675

Acquisition - Intangible Assets

Acquisition - Intangible Assets Acquired (Details) - Tetramer Shop $ in Thousands	Jan. 08, 2021USD ($)
Business Acquisition [Line Items]
Intangible assets	$ 5,640
Developed technology
Business Acquisition [Line Items]
Intangible assets	$ 5,500
Weighted Average Useful Life (in years)	10 years
Customer relationships
Business Acquisition [Line Items]
Intangible assets	$ 140
Weighted Average Useful Life (in years)	3 years

Other Financial Statement Inf_3

Other Financial Statement Information - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Purchased materials	$ 25,995	$ 9,930
Work in progress	12,742	9,312
Finished goods	12,404	10,717
Inventory	$ 51,141	$ 29,959

Other Financial Statement Inf_4

Other Financial Statement Information - Schedule Of Property Plant And Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 186,983	$ 103,342
Less: accumulated depreciation and amortization	(44,394)	(30,502)
Property and equipment, net	142,589	72,840
Land
Property, Plant and Equipment [Line Items]
Total property and equipment	35,692	0
Laboratory equipment and machinery
Property, Plant and Equipment [Line Items]
Total property and equipment	42,017	30,010
Computer equipment and software
Property, Plant and Equipment [Line Items]
Total property and equipment	11,844	5,783
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment	5,647	5,887
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	52,941	42,068
Construction in progress
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 38,842	$ 19,594

Other Financial Statement Inf_5

Other Financial Statement Information - Intangible Assets, Net (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 30,281	$ 24,641
Accumulated Amortization	(4,240)	(2,287)
Intangibles, Net	$ 26,041	$ 22,354
Technology licenses
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	13 years	13 years 8 months 12 days
Gross Carrying Amount	$ 22,504	$ 22,504
Accumulated Amortization	(3,123)	(1,973)
Intangibles, Net	$ 19,381	20,531
Developed technology
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	9 years 3 months 18 days
Gross Carrying Amount	$ 5,500	0
Accumulated Amortization	(413)	0
Intangibles, Net	$ 5,087	$ 0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	3 years	3 years 10 months 24 days
Gross Carrying Amount	$ 945	$ 805
Accumulated Amortization	(280)	(111)
Intangibles, Net	$ 665	$ 694
Trademarks
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	1 month 6 days	10 months 24 days
Gross Carrying Amount	$ 204	$ 204
Accumulated Amortization	(193)	(142)
Intangibles, Net	$ 11	$ 62
Assembled workforce
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life in Years	4 years	4 years 9 months 18 days
Gross Carrying Amount	$ 1,128	$ 1,128
Accumulated Amortization	(231)	(61)
Intangibles, Net	$ 897	$ 1,067

Other Financial Statement Inf_6

Other Financial Statement Information - Annual Amortization of Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
2021 (excluding the nine months ended September 30, 2021)	$ 645
2022	2,535
2023	2,506
2024	2,378
2025	2,214
Thereafter	15,763
Intangibles, Net	$ 26,041	$ 22,354

Other Financial Statement Inf_7

Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and related costs	$ 3,470	$ 2,506
Employee stock purchase program liability	3,567	1,258
Accrued bonus	12,200	5,058
Accrued commissions	3,001	3,038
Accrued acquisition-related compensation	2,968	2,213
Accrued vacation	1,287	1,035
Other	689	275
Accrued compensation and related benefits	$ 27,182	$ 15,383

Other Financial Statement Inf_8

Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued legal and related costs	$ 3,327	$ 5,704
Accrued license fee	5,999	6,198
Accrued purchase consideration	5,015	4,146
Accrued royalties for licensed technologies	4,143	3,160
Accrued property and equipment	12,515	2,983
Accrued professional services	5,400	3,137
Product warranties	824	399
Customer deposits	962	1,727
Taxes payable	3,300	8,649
Accrued lab supplies	1,875	1,506
Other	2,827	5,844
Accrued expenses and other current liabilities	$ 46,187	$ 43,453

Other Financial Statement Inf_9

Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning of period	$ 399	$ 467
Amounts charged to cost of revenue	2,113	796
Repairs and replacements	(1,688)	(864)
End of period	$ 824	$ 399

Other Financial Statement In_10

Other Financial Statement Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Concentration Risk [Line Items]
Transaction price allocated to remaining performance obligations	$ 7,300		$ 7,300
Contract liability	7,300		7,300		$ 6,200
Deferred revenue	5,505		5,505		$ 4,472
Contract with customer, liability, revenue recognized	900	$ 700	3,400	$ 2,800
Products and Services, Excluding Grant Revenue
Concentration Risk [Line Items]
Deferred revenue	$ 5,400		$ 5,400
Revenue | Geographic Concentration Risk | UNITED STATES
Concentration Risk [Line Items]
Percentage of revenue	55.00%	57.00%	53.00%	53.00%

Other Financial Statement In_11

Other Financial Statement Information - Revenue Recognition (Details)	Sep. 30, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected period of revenue recognition	12 months

Other Financial Statement In_12

Other Financial Statement Information - Schedule of Revenue by Source (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue from External Customer [Line Items]
Revenue	$ 125,297	$ 71,817	$ 346,960	$ 186,627
Instruments
Revenue from External Customer [Line Items]
Revenue	17,121	9,676	45,123	26,108
Consumables
Revenue from External Customer [Line Items]
Revenue	106,117	60,557	296,342	156,149
Services
Revenue from External Customer [Line Items]
Revenue	$ 2,059	$ 1,584	$ 5,495	$ 4,370

Other Financial Statement In_13

Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 125,297	$ 71,817	$ 346,960	$ 186,627
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	70,228	42,363	187,800	102,356
Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	25,819	15,497	73,761	40,370
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	19,063	8,689	55,577	27,314
Asia-Pacific (excluding China)
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 10,187	$ 5,268	$ 29,822	$ 16,587

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 18, 2020	Feb. 20, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 0	$ 0	$ 0	$ (1,521)
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, termination fee	$ 300
Line of credit, outstanding	$ 0
Tranche A | Term Loan
Debt Instrument [Line Items]
Early payment of debt		$ 30,500
Early payment of debt principal amount		28,300
Early payment, term payment		1,800
Early payment of debt termination fees		300
Early payment of debt interest amount		100
Loss on extinguishment of debt		$ 1,500

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	3 Months Ended			9 Months Ended		117 Months Ended
	Sep. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2030USD ($)	Apr. 30, 2021USD ($)ft²	Mar. 31, 2021USD ($)	Nov. 06, 2020USD ($)ft²
Loss Contingencies [Line Items]
Operating lease costs	$ 2,600		$ 2,100	$ 7,900	$ 6,100
Variable lease costs	100		19	500	200
Operating lease payment				4,600	5,100
Reversal of accrued royalties and interest	0		$ (332)	660	$ (956)
Pleasanton, California
Loss Contingencies [Line Items]
Lease payment commencing 2022	21,000			21,000
Lease payment commencing 2023	$ 14,000			$ 14,000
Pleasanton, California | 2022
Loss Contingencies [Line Items]
Weighted-average expected lease terms	12 years			12 years
Pleasanton, California | 2023
Loss Contingencies [Line Items]
Weighted-average expected lease terms	11 years			11 years
Additional office building
Loss Contingencies [Line Items]
Lease payment commencing 2022	$ 1,054			$ 1,054
Lease payment commencing 2023	2,855			2,855
Operating lease not yet commenced	40,700			40,700
Additional office building | Pleasanton, California
Loss Contingencies [Line Items]
Real estate property, area | ft²									145,000
Expected total lease payments									$ 60,800
Tenant improvement allowance									$ 10,000
Tenant improvement allowance received	$ 2,600			$ 2,600
Additional office building | Stockholm, Sweden
Loss Contingencies [Line Items]
Real estate property, area | ft²							22,000
Weighted-average expected lease terms							5 years
Operating lease not yet commenced							$ 5,700
Bio RadLaboratories Inc
Loss Contingencies [Line Items]
Loss contingency								$ 44,800
Reversal of accrued royalties and interest		$ 15,400
Bio RadLaboratories Inc | Forecast
Loss Contingencies [Line Items]
Loss contingency payments						$ 29,400
Maximum
Loss Contingencies [Line Items]
Operating lease term	12 years			12 years

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Company's Operating Lease Liabilities (Detail) $ in Thousands	Sep. 30, 2021USD ($)
Operating Leases
2021 (excluding the nine months ended September 30, 2021)	$ 464
2022	9,969
2023	11,637
2024	10,942
2025	11,152
Thereafter	59,746
Total lease payments	103,910
Less: imputed interest	(23,711)
Present value of operating lease liabilities	80,199
Operating lease liabilities, current	4,464
Operating lease liabilities, noncurrent	$ 75,735

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail)	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Weighted-average remaining lease term, operating leases	7 years 7 months 6 days	8 years 4 months 24 days
Weighted-average discount rate, operating leases	5.40%	4.50%

Commitments and Contingencies_4

Commitments and Contingencies - Estimated Undiscounted Lease Payments (Details) - Additional office building $ in Thousands	Sep. 30, 2021USD ($)
Lessee, Lease, Description [Line Items]
2021 (excluding the nine months ended September 30, 2021)	$ 0
2022	1,054
2023	2,855
2024	4,342
2025	4,179
Thereafter	28,270
Total undiscounted lease payments	$ 40,700

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Shares Converted From Class B to Class A
Class of Stock [Line Items]
Conversion of stock, shares converted (in shares)	0	2,153,783	2,400,000	47,558,717
Common Class A
Class of Stock [Line Items]
Common stock shares issued (in shares)	91,255,983		91,255,983
Common stock shares outstanding (in shares)	91,255,983		91,255,983
Common Class B
Class of Stock [Line Items]
Common stock shares issued (in shares)	20,281,465		20,281,465
Common stock shares outstanding (in shares)	20,281,465		20,281,465

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail) - Common Class A - 2019 Employee Stock Purchase Plan - Employee Stock - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)	2,888,340		2,888,340		3,084,859
Share-based compensation arrangement percent			85.00%
Holding period following purchase			1 year
Shares issued in period for previously outstanding awards (in shares)	0	0	30,980	118,218

Equity Incentive Plans - Record

Equity Incentive Plans - Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 25,950	$ 13,784	$ 69,058	$ 34,357
Cost of revenue
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	878	398	2,183	1,108
Research and development
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	11,226	5,467	30,162	14,398
Selling, general and administrative
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 13,846	$ 7,919	$ 36,713	$ 18,851

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of RSU Activity (Detail)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Restricted Stock Units
Restricted Stock Units, Beginning balance (in shares) | shares	823,947
Restricted Stock Units, Granted (in shares) | shares	828,463
Restricted Stock Units, Vested (in shares) | shares	(266,602)
Restricted Stock Units, Cancelled (in shares) | shares	(71,651)
Restricted Stock Units, Ending balance (in shares) | shares	1,314,157
Weighted-Average Grant Date Fair Value (per share)
Weighted-Average Grant Date Fair Value, Beginning balance (in dollars per share) | $ / shares	$ 80.97
Weighted-Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	184.38
Weighted-Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares	106.14
Weighted-Average Grant Date Fair Value, Cancelled (in dollars per share) | $ / shares	118.67
Weighted-Average Grant Date Fair Value, Ending balance (in dollars per share) | $ / shares	$ 139

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary of Company's Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Stock Options
Outstanding stock options, Beginning balance (in shares) | shares	11,860,844
Outstanding stock options - Granted (in shares) | shares	363,874
Outstanding stock options - Exercised (in shares) | shares	(2,753,957)
Outstanding stock options - Cancelled (in shares) | shares	(263,911)
Outstanding stock options, Ending balance (in shares) | shares	9,206,850
Weighted-Average Exercise Price
Weighted-average exercise price - Beginning balance (in dollars per share) | $ / shares	$ 18.86
Weighted-average exercise price - Granted (in dollars per share) | $ / shares	178.40
Weighted-average exercise price - Exercised (in dollars per share) | $ / shares	10.11
Weighted-average exercise price - Cancelled (in dollars per share) | $ / shares	25
Weighted-average exercise price - Ending balance (in dollars per share) | $ / shares	$ 27.61

Net Loss Per Share - Shares of

Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	10,811,669	13,720,262	10,811,669	13,720,262
Stock-options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	9,206,850	12,817,142	9,206,850	12,817,142
Shares subject to repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	25,000	84,375	25,000	84,375
Contingent restricted shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	236,484	0	236,484	0
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	1,314,157	779,296	1,314,157	779,296
Shares committed under ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	29,178	39,449	29,178	39,449